Why are acute ischemic stroke patients not receiving IV tPA?: Results from a national registry

Neurology

Volumn 87, Issue 15, 2016, Pages 1565-1574

  Messé, Steven R ^a   Khatri, Pooja ^b   Reeves, Mathew J ^c   Smith, Eric E ^d   Saver, Jeffrey L ^e   Bhatt, Deepak L ^g   Grau Sepulveda, Maria V ^h   Cox, Margueritte ^h   Peterson, Eric D ⁱ   Fonarow, Gregg C ^f   Schwamm, Lee H ^j  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALGARY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h DUKE CLINICAL RESEARCH INSTITUTE   (United States)

ⁱ DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR; FIBRINOLYTIC AGENT;

AGE; AGED; ARTICLE; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; CAUCASIAN; COHORT ANALYSIS; DIABETES MELLITUS; DISABILITY SEVERITY; EMERGENCY HEALTH SERVICE; FEMALE; FIBRINOLYTIC THERAPY; HEART VALVE PROSTHESIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; ONSET AGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; HEALTH CARE DISPARITY; INFORMATION PROCESSING; INTRAVENOUS DRUG ADMINISTRATION; MULTIVARIATE ANALYSIS; REGISTER; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STROKE; UNITED STATES; VERY ELDERLY;

ADMINISTRATION, INTRAVENOUS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; DATASETS AS TOPIC; FEMALE; FIBRINOLYTIC AGENTS; HEALTHCARE DISPARITIES; HUMANS; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; REGISTRIES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; UNITED STATES;

EID: 84992061035     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000003198     Document Type: Article

References (41)

1. rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-1329.
3. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet 2012;379:2364-2372.
4. Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e601S-e636S.
5. Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.
6. Edlow J, Smith E, Stead L, et al. Clinical policy: use of intravenous tPA for the management of acute ischemic stroke in the emergency department. Ann Emerg Med 2013;61:225-243.
7. Adeoye O, Hornung R, Khatri P, Kleindorfer D. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Stroke 2011;42: 1952-1955.
8. Schwamm LH, Ali SF, Reeves MJ, et al. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013;6:543-549.
9. Lin CB, Peterson ED, Smith EE, et al. Patterns, predictors, variations, and temporal trends in emergency medical service hospital prenotification for acute ischemic stroke. J Am Heart Assoc 2012;1:e002345.
10. Reeves MJ, Fonarow GC, Smith EE, et al. Representativeness of the Get With The Guidelines-Stroke Registry: comparison of patient and hospital characteristics among Medicare beneficiaries hospitalized with ischemic stroke. Stroke 2012;43:44-49.
11. Messe SR, Fonarow GC, Smith EE, et al. Use of tissuetype plasminogen activator before and after publication of the European Cooperative Acute Stroke Study III in Get With The Guidelines-Stroke. Circ Cardiovasc Qual Outcomes 2012;5:321-326.
12. LaBresh KA, Reeves MJ, Frankel MR, Albright D, Schwamm LH. Hospital treatment of patients with ischemic stroke or transient ischemic attack using the "Get With The Guidelines" program. Arch Intern Med 2008; 168:411-417.
13. Schwamm LH, Fonarow GC, Reeves MJ, et al. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack. Circulation 2009;119: 107-115.
14. Xian Y, Fonarow GC, Reeves MJ, et al. Data quality in the American Heart Association Get With The Guidelines-Stroke (GWTG-Stroke): results from a national data validation audit. Am Heart J 2012;163:392-398, 398.e391.
15. Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009;40:2945-2948.
16. Fonarow GC, Saver JL, Smith EE, et al. Relationship of National Institutes of Health Stroke Scale to 30-day mortality in Medicare beneficiaries with acute ischemic stroke. J Am Heart Assoc 2012;1:42-50.
17. Fonarow GC, Liang L, Smith EE, et al. Comparison of performance achievement award recognition with primary stroke center certification for acute ischemic stroke care. J Am Heart Assoc 2013;2:e000451.
18. Cruz-Flores S, Rabinstein A, Biller J, et al. Racial-ethnic disparities in stroke care: the American experience: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42: 2091-2116.
19. Johnston SC, Fung LH, Gillum LA, et al. Utilization of intravenous tissue-type plasminogen activator for ischemic stroke at academic medical centers: the influence of ethnicity. Stroke 2001;32:1061-1068.
20. Reed SD, Cramer SC, Blough DK, Meyer K, Jarvik JG. Treatment with tissue plasminogen activator and inpatient mortality rates for patients with ischemic stroke treated in community hospitals. Stroke 2001;32:1832-1840.
21. Giralt D, Domingues-Montanari S, Mendioroz M, et al. The gender gap in stroke: a meta-analysis. Acta Neurol Scand 2012;125:83-90.
22. Towfighi A, Markovic D, Ovbiagele B. Sex differences in revascularization interventions after acute ischemic stroke. J Stroke Cerebrovasc Dis 2013;22:e347-e353.
23. Nasr DM, BrinjikjiW, Cloft HJ, Rabinstein AA. Racial and ethnic disparities in the use of intravenous recombinant tissue plasminogen activator and outcomes for acute ischemic stroke. J Stroke Cerebrovasc Dis 2011;22:154-160.
24. Reeves M, Bhatt A, Jajou P, Brown M, Lisabeth L. Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. Stroke 2009;40:1743-1749.
25. ReevesMJ, Fonarow GC, Zhao X, Smith EE, Schwamm LH. Quality of care in women with ischemic stroke in the GWTG program. Stroke 2009;40:1127-1133.
26. Schwamm LH, Reeves MJ, Pan W, et al. Race/ethnicity, quality of care, and outcomes in ischemic stroke. Circulation 2010;121:1492-1501.
27. Hills NK, Johnston SC. Why are eligible thrombolysis candidates left untreated? Am J Prev Med 2006;31:S210-S216.
28. Rost NS, Smith EE, Pervez MA, Mello P, Dreyer P, Schwamm LH. Predictors of increased intravenous tissue plasminogen activator use among hospitals participating in the Massachusetts Primary Stroke Service Program. Circ Cardiovasc Qual Outcomes 2012;5:314-320.
29. Shamy MC, Jaigobin CS. The complexities of acute stroke decision-making: a survey of neurologists. Neurology 2013;81:1130-1133.
30. Mishra NK, Ahmed N, Andersen G, et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive. BMJ 2010;341:c6046.
31. Mishra NK, Diener HC, Lyden PD, Bluhmki E, Lees KR. Influence of age on outcome from thrombolysis in acute stroke: a controlled comparison in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke 2010;41:2840-2848.
32. Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the Third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet 2013;379: 2352-2363.
33. Emberson J, Lees KR, Lyden P, et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-1935.
34. Barber PA, Zhang J, Demchuk AM, HillMD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56: 1015-1020.
35. Kleindorfer D, Kissela B, Schneider A, et al. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke 2004;35: e27-e29.
36. Khatri P, Conaway MR, Johnston KC. Ninety-day outcome rates of a prospective cohort of consecutive patients with mild ischemic stroke. Stroke 2011;43:560-562.
37. Smith EE, Abdullah AR, Petkovska I, Rosenthal E, Koroshetz WJ, Schwamm LH. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke. Stroke 2005;36:2497-2499.
38. Khatri P, Tayama D, Cohen G, et al. Effect of intravenous recombinant tissue-type plasminogen activator in patients with mild stroke in the Third International Stroke Trial-3: post hoc analysis. Stroke 2015;46:2325-2327.
39. Meretoja A, Weir L, Ugalde M, et al. Helsinki model cut stroke thrombolysis delays to 25 minutes in Melbourne in only 4 months. Neurology 2013;81:1071-1076.
40. Fonarow GC, Zhao X, Smith EE, et al. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative. JAMA 2014;311: 1632-1640.
41. ReevesMJ, Grau-SepulvedaMV, Fonarow GC, Olson DM, Smith EE, Schwamm LH. Are quality improvements in the Get With The Guidelines: Stroke program related to better care or better data documentation? Circ Cardiovasc Qual Outcomes 2011;4:503-511.